JP2019533450A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533450A5
JP2019533450A5 JP2019521099A JP2019521099A JP2019533450A5 JP 2019533450 A5 JP2019533450 A5 JP 2019533450A5 JP 2019521099 A JP2019521099 A JP 2019521099A JP 2019521099 A JP2019521099 A JP 2019521099A JP 2019533450 A5 JP2019533450 A5 JP 2019533450A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
isoform
composition according
cells
surface protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019521099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533450A (ja
JP7305539B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2017/059799 external-priority patent/WO2017186718A1/en
Application filed filed Critical
Priority claimed from PCT/EP2017/077826 external-priority patent/WO2018083071A1/en
Publication of JP2019533450A publication Critical patent/JP2019533450A/ja
Publication of JP2019533450A5 publication Critical patent/JP2019533450A5/ja
Priority to JP2023105962A priority Critical patent/JP7676472B2/ja
Application granted granted Critical
Publication of JP7305539B2 publication Critical patent/JP7305539B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019521099A 2016-11-02 2017-10-30 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体 Active JP7305539B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023105962A JP7676472B2 (ja) 2016-11-02 2023-06-28 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16196860.7 2016-11-02
EP16196860 2016-11-02
EP16196858.1 2016-11-02
EP16196858 2016-11-02
EPPCT/EP2017/059799 2017-04-25
PCT/EP2017/059799 WO2017186718A1 (en) 2016-04-25 2017-04-25 Allele editing and applications thereof
EP17197820 2017-10-23
EP17197820.8 2017-10-23
PCT/EP2017/077826 WO2018083071A1 (en) 2016-11-02 2017-10-30 Immunologically discernible cell surface variants for use in cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023105962A Division JP7676472B2 (ja) 2016-11-02 2023-06-28 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体

Publications (3)

Publication Number Publication Date
JP2019533450A JP2019533450A (ja) 2019-11-21
JP2019533450A5 true JP2019533450A5 (cg-RX-API-DMAC7.html) 2020-12-03
JP7305539B2 JP7305539B2 (ja) 2023-07-10

Family

ID=62075802

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521099A Active JP7305539B2 (ja) 2016-11-02 2017-10-30 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体
JP2023105962A Active JP7676472B2 (ja) 2016-11-02 2023-06-28 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023105962A Active JP7676472B2 (ja) 2016-11-02 2023-06-28 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体

Country Status (21)

Country Link
US (1) US20190365806A1 (cg-RX-API-DMAC7.html)
EP (2) EP3535392B1 (cg-RX-API-DMAC7.html)
JP (2) JP7305539B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240043810A (cg-RX-API-DMAC7.html)
CN (1) CN110191948A (cg-RX-API-DMAC7.html)
AU (1) AU2017355218B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019008975A2 (cg-RX-API-DMAC7.html)
CA (1) CA3041582A1 (cg-RX-API-DMAC7.html)
DK (1) DK3535392T3 (cg-RX-API-DMAC7.html)
ES (1) ES2977969T3 (cg-RX-API-DMAC7.html)
FI (1) FI3535392T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240842T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067685T2 (cg-RX-API-DMAC7.html)
IL (1) IL266362B2 (cg-RX-API-DMAC7.html)
LT (1) LT3535392T (cg-RX-API-DMAC7.html)
MX (1) MX2019005125A (cg-RX-API-DMAC7.html)
PL (1) PL3535392T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201903454VA (cg-RX-API-DMAC7.html)
SI (1) SI3535392T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018083071A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201902426B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
IL258491B2 (en) 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
EP3448995A1 (en) * 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
ES3024357T3 (en) * 2017-02-17 2025-06-04 Purdue Research Foundation Targeted ligand-payload based drug delivery for cell therapy
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
SI3710067T1 (sl) 2017-11-14 2026-01-30 Arcellx, Inc. Polipeptidi, ki vsebujejo D-domeno, in njihova uporaba
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
ES3061216T3 (en) 2018-06-29 2026-03-31 Hope City Cd6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US20220160870A1 (en) * 2018-08-28 2022-05-26 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
EP3908372A1 (en) * 2019-01-13 2021-11-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human nectin-2
KR102689877B1 (ko) * 2019-11-28 2024-08-01 주식회사 센트릭스바이오 CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체
US12616734B2 (en) 2019-11-28 2026-05-05 CentricsBio, Inc. Chimeric antigen receptor specifically binding to cd 300C antigen or receptor thereof
US20230076643A1 (en) * 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
KR102347797B1 (ko) * 2020-03-03 2022-01-07 한국과학기술원 대식세포 세포 표면 항원 및 이의 다양한 용도
EP4126243A4 (en) * 2020-03-27 2024-06-12 The Trustees of Indiana University Immunotherapeutic targets in multiple myeloma and methods for their identification
AU2021413252A1 (en) * 2020-12-31 2023-06-08 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
WO2022150831A1 (en) * 2021-01-07 2022-07-14 Innovative Cellular Therapeutics Holdings, Ltd. Car cells and polyspecific binding molecules for treating solid tumor
CN112852875B (zh) * 2021-02-26 2022-10-21 福建省立医院 示踪肿瘤T淋巴细胞浸润的CD3e转基因小鼠模型的构建方法
CN113125754A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的23抗体试剂盒及应用
CN113125755A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的9抗体试剂盒及应用
CN113109575A (zh) * 2021-04-16 2021-07-13 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的40抗体试剂盒及应用
CN113125718A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的45抗体试剂盒及应用
CN113125733A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的42抗体试剂盒及应用
WO2022246764A1 (zh) * 2021-05-27 2022-12-01 中科蓝华(广州)生物医药技术有限公司 一种分析cd303+树突状细胞亚群表型和功能的方法及试剂盒
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
EP4381062A1 (en) 2021-08-02 2024-06-12 Vor Biopharma Inc. Compositions and methods for gene modification
EP4380693A1 (en) 2021-08-06 2024-06-12 Universität Basel Discernible cell surface protein variants for use in cell therapy
IL313568A (en) 2021-12-16 2024-08-01 Universit?T Basel Distinct cell membrane protein variants of CD117 for use in cellular therapy
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
CN114292830B (zh) * 2021-12-31 2024-05-03 复旦大学 蛋白SaCas9的抗原表位及其在基因编辑中的应用
WO2024015925A2 (en) * 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
EP4611807A4 (en) * 2022-11-04 2026-07-29 Univ Leland Stanford Junior REBALANCING OF THE IMMUNE SYSTEM BY DEPLOYMENT OF HEMATOPOIETIC STEM CELLS ORIENTED TO MYELOID PRODUCTION
CN116153401B (zh) * 2023-01-07 2024-01-05 杭州链康医学检验实验室有限公司 基于pdx的单细胞转录组数据分析方法、系统、设备和介质
JP2026516593A (ja) 2023-04-03 2026-05-26 ウニバズィテート バーゼル 細胞治療に使用するためのcd33の識別可能な表面タンパク質変異体
EP4753751A1 (en) 2023-08-04 2026-06-10 Cimeio Therapeutics AG Discernible cell surface protein variants of cd52 for use in cell therapy
WO2025132801A1 (en) 2023-12-19 2025-06-26 Cimeio Therapeutics Ag Discernible protein variants of bcl-2 for use in cell therapy
CN120738344A (zh) * 2025-08-26 2025-10-03 北京康美天鸿生物科技有限公司 检测地中海贫血基因突变的引物组及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002240745A1 (en) * 2001-03-07 2002-09-19 Andre Schuh Diagnosis and treatment of blood disorders
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2007087453A2 (en) * 2006-01-27 2007-08-02 Cellerant Therapeutics, Inc. Compositions and methods for treating haematological proliferative disorders
EP3255061B1 (en) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
US8697846B2 (en) * 2007-08-15 2014-04-15 Emory University Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology
JP5688734B2 (ja) * 2008-12-12 2015-03-25 国立大学法人 東京大学 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤
DK3363902T3 (da) * 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
CN111363047A (zh) * 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
EP3569253A1 (en) * 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
KR20160020554A (ko) * 2013-06-17 2016-02-23 슈 생-쥐스땡 척추측만 개체의 세포에서 gipcr 신호전달을 증가시키는 방법
WO2016014837A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
US10201606B2 (en) * 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
EP3370741B1 (en) * 2015-11-04 2025-10-08 The Trustees of the University of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
JP2019508037A (ja) * 2016-02-16 2019-03-28 イェール ユニバーシティーYale Universit 標的化遺伝子編集を増強するための組成物およびその使用方法
IL313038A (en) * 2016-03-14 2024-07-01 Editas Medicine Inc Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
EP3448995A1 (en) * 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof

Similar Documents

Publication Publication Date Title
JP2023126852A5 (cg-RX-API-DMAC7.html)
HRP20240842T1 (hr) Imunološki uočljive varijante stanične površine za upotrebu u staničnoj terapiji
JP2023515199A5 (cg-RX-API-DMAC7.html)
IL295897A (en) Materials and methods for modulating an immune response
HRP20200251T1 (hr) Proizvodnja i korištenje vitro-sintetizirane ssrna za uvođenje u ćelije sisavaca za proizvodnju biološkog ili biokemijskog učinka
JP2025517657A5 (cg-RX-API-DMAC7.html)
JP2024506682A5 (cg-RX-API-DMAC7.html)
JP2025513879A5 (cg-RX-API-DMAC7.html)
JP2023537534A5 (cg-RX-API-DMAC7.html)
JP2004528806A5 (cg-RX-API-DMAC7.html)
JP2017200474A5 (cg-RX-API-DMAC7.html)
JP2022534813A (ja) Cd33改変のための組成物および方法
US20240408234A1 (en) Compositions and methods for multiplex base editing in hematopoietic cells
WO2022061115A1 (en) Compositions and methods for cd7 modification
US20230364233A1 (en) Compositions and methods for cd6 modification
US20240417755A1 (en) Fusion polypeptides for genetic editing and methods of use thereof
WO2022217086A1 (en) Photocleavable guide rnas and methods of use thereof
EP4430186A1 (en) Compositions and methods for erm2 modification
US20240384304A1 (en) Inhibitor oligonucleotides and methods of use thereof
AU2024369017A1 (en) SIRPα ENGAGER CELLS
RU2793803C2 (ru) Иммунологически отличимые варианты поверхности клеток для применения в клеточной терапии
HK40014655A (en) Immunologically discernible cell surface variants for use in cell therapy
HK40014655B (en) Immunologically discernible cell surface variants for use in cell therapy